ERBB2 and rhabdomyosarcoma: Intriguingly, she emphasized that CIK-FFM cells can be engineered in-vitro with a second-generation CAR targeting, for example, the tumor-associated surface antigen ErbB2 (HER2/neu), a therapeutically useful target found in rhabdomyosarcoma (RMS) and other solid tumor entities.